Quest Diagnostics Incorporated Expected to Post FY2025 Earnings of $9.29 Per Share (NYSE:DGX)

Quest Diagnostics Incorporated (NYSE:DGX) – Equities researchers at Zacks Research lifted their FY2025 earnings per share (EPS) estimates for Quest Diagnostics in a note issued to investors on Thursday, June 20th. Zacks Research analyst M. Mondal now forecasts that the medical research company will earn $9.29 per share for the year, up from their prior estimate of $9.28. The consensus estimate for Quest Diagnostics’ current full-year earnings is $8.79 per share.

Quest Diagnostics (NYSE:DGX) last announced its earnings results on Tuesday, April 23rd. The medical research company reported $2.04 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $1.86 by $0.18. The company had revenue of $2.37 billion for the quarter, compared to analyst estimates of $2.29 billion. Quest Diagnostics had a return on equity of 15.52% and a net margin of 9.11%. The firm’s quarterly revenue was up 1.7% compared to the same quarter last year. During the same quarter in the previous year, the company earned $2.04 earnings per share.

Other equities research analysts also recently issued research reports about the stock. Citigroup increased their target price on shares of Quest Diagnostics from $135.00 to $145.00 and gave the stock a “neutral” rating in a research note on Wednesday, April 24th. Leerink Partnrs reissued a “market perform” rating on shares of Quest Diagnostics in a research note on Monday, February 26th. Truist Financial raised their price objective on shares of Quest Diagnostics from $145.00 to $150.00 and gave the stock a “hold” rating in a research note on Wednesday, April 24th. Mizuho raised their price objective on shares of Quest Diagnostics from $150.00 to $155.00 and gave the stock a “buy” rating in a research note on Wednesday, April 24th. Finally, SVB Leerink initiated coverage on shares of Quest Diagnostics in a research note on Monday, February 26th. They issued a “market perform” rating and a $135.00 target price for the company. Nine equities research analysts have rated the stock with a hold rating and four have issued a buy rating to the stock. According to MarketBeat, Quest Diagnostics has a consensus rating of “Hold” and an average price target of $146.67.

Quest Diagnostics Stock Up 0.9 %

Quest Diagnostics stock opened at $140.23 on Monday. The firm has a market capitalization of $15.58 billion, a P/E ratio of 18.87, a P/E/G ratio of 3.00 and a beta of 0.89. The stock’s fifty day simple moving average is $138.24 and its 200-day simple moving average is $133.74. The company has a current ratio of 0.97, a quick ratio of 0.89 and a debt-to-equity ratio of 0.59. Quest Diagnostics has a twelve month low of $119.59 and a twelve month high of $145.62.

Institutional Inflows and Outflows

Institutional investors and hedge funds have recently made changes to their positions in the stock. FMR LLC boosted its holdings in Quest Diagnostics by 16.2% during the third quarter. FMR LLC now owns 1,305,532 shares of the medical research company’s stock worth $159,092,000 after buying an additional 182,005 shares in the last quarter. Fuller & Thaler Asset Management Inc. lifted its position in shares of Quest Diagnostics by 9.9% in the 3rd quarter. Fuller & Thaler Asset Management Inc. now owns 6,645 shares of the medical research company’s stock valued at $810,000 after acquiring an additional 600 shares in the last quarter. Stifel Financial Corp lifted its position in shares of Quest Diagnostics by 6.3% in the 3rd quarter. Stifel Financial Corp now owns 72,385 shares of the medical research company’s stock valued at $8,821,000 after acquiring an additional 4,280 shares in the last quarter. Federated Hermes Inc. purchased a new stake in shares of Quest Diagnostics in the 3rd quarter valued at approximately $51,000. Finally, Meiji Yasuda Asset Management Co Ltd. lifted its position in shares of Quest Diagnostics by 87.8% in the 3rd quarter. Meiji Yasuda Asset Management Co Ltd. now owns 8,362 shares of the medical research company’s stock valued at $1,019,000 after acquiring an additional 3,910 shares in the last quarter. 88.06% of the stock is currently owned by institutional investors.

Insiders Place Their Bets

In other Quest Diagnostics news, SVP Karthik Kuppusamy sold 1,760 shares of the company’s stock in a transaction dated Monday, April 29th. The shares were sold at an average price of $140.00, for a total value of $246,400.00. Following the completion of the transaction, the senior vice president now owns 13,435 shares in the company, valued at approximately $1,880,900. The transaction was disclosed in a legal filing with the SEC, which is available through the SEC website. 0.79% of the stock is owned by insiders.

Quest Diagnostics Announces Dividend

The company also recently announced a quarterly dividend, which will be paid on Monday, July 22nd. Shareholders of record on Monday, July 8th will be given a $0.75 dividend. This represents a $3.00 annualized dividend and a yield of 2.14%. The ex-dividend date of this dividend is Monday, July 8th. Quest Diagnostics’s dividend payout ratio (DPR) is 40.38%.

About Quest Diagnostics

Quest Diagnostics Incorporated provides diagnostic testing and services in the United States and internationally. The company develops and delivers diagnostic information services, such as routine, non-routine and advanced clinical testing, anatomic pathology testing, and other diagnostic information services.